A health economic model to assess the long term effects and cost-effectiveness of PEG IFN a-2a in hepatitis C virus infected patients
| Journal | Volume 67 - 2004 |
| Issue | Fasc.1 - Original articles |
| Author(s) | L. Annemans, H. Warie, M. Nechelput, B. Peraux |
| Full article |
 VIEW FREE PDF |
| (1) HEDM, Meise, Belgium ; (2) Ghent University , Ghent, Belgium ; (3) Roche Pharmaceuticals, Brussels, Belgium. |
|
Objectives : Chronic Hepatitis C (CHC) is associated with long- term complications. Treating CHC with Pegylated interferon a-2a (PEG IFN a-2a) improves response rates and may contribute to less morbidity and mortality compared to standard interferon therapy. The objectives of this study were to estimate the long- term clinical consequences of such treatment as well as the result- ing cost-effectiveness. |
|
© Acta Gastro-Enterologica Belgica. |
